INSM supply chain intelligence for Insmed Incorporated: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ESTEVE-QU-MICA-S-A | ESTEVE-QU-MICA-S-A | 92% | In September 2024, we entered into a commercial manufacturing and supply agreement with Esteve Química, S.A. (Esteve) for the manufacture and supply of brensocatib's active pharmaceutical ingredient. |
| PARI | PARI | 92% | We have a commercialization agreement with PARI, the manufacturer of our drug delivery nebulizer for ARIKAYCE, to address our commercial supply needs (the Commercialization Agreement). |
| RESILIENCE-BIOTECHNOLOGIES-INC | RESILIENCE-BIOTECHNOLOGIES-INC | 92% | ARIKAYCE is manufactured currently by Resilience Biotechnologies Inc. (Resilience) (formerly Therapure Biopharma Inc.) in Canada at a 200 kilogram (kg) scale. |
| ORANY | ORANY | 72% | evelopment industry has a history of intellectual property litigation, and we may become involved in costly intellectual property disputes, which may delay or impair our product development efforts o… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from INSM graph: evelopment industry has a history of intellectual property litigation, and we may become involved in costly intellec… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CYSTIC-FIBROSIS-FOUNDATION-THERAPEUTICS-INC | CYSTIC-FIBROSIS-FOUNDATION-THERAPEUTICS-INC | 90% | In 2004 and 2009, we entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) whereby we received $1.7 million and $2.2 million in research funding for the d… |
| BIOPHARMA-CREDIT-PLC-BPCR-LIMITED | BIOPHARMA-CREDIT-PLC-BPCR-LIMITED | 62% | mercial activities in p reparation for a launch of brensocatib for patients with bronchiectasis. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, t… |
| BRIDGEWATER-BIOTECH-CENTER-LLC | BRIDGEWATER-BIOTECH-CENTER-LLC | 62% | mercial activities in p reparation for a launch of brensocatib for patients with bronchiectasis. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, t… |
| INITIAL-TERM-RESILIENCE-BIOTECHNOLOGIES-INC | INITIAL-TERM-RESILIENCE-BIOTECHNOLOGIES-INC | 62% | . Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days’ written notice, (ii) any project addendum in the event of the … |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | mercial activities in p reparation for a launch of brensocatib for patients with bronchiectasis. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, t… |
| SVB-LEERINK-LLC | SVB-LEERINK-LLC | 62% | mercial activities in p reparation for a launch of brensocatib for patients with bronchiectasis. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, t… |
| THERAPURE-BIOPHARMA-INC | THERAPURE-BIOPHARMA-INC | 62% | . Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days’ written notice, (ii) any project addendum in the event of the … |
| TPIP-PATHEON-UK-LIMITED | TPIP-PATHEON-UK-LIMITED | 62% | . Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days’ written notice, (ii) any project addendum in the event of the … |
| VERTUIS-BIO-INC | VERTUIS-BIO-INC | 62% | become entitled to receive contingent payments up to an aggregate of $ 326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalt… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| INSM-DEBT-10301 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| INSM-DEBT | Debt stack $742.5M | 90% | Market cache reports total debt of $742.5M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| INSM-OWNER-JPMORGAN-CHASE-CO | JPMORGAN CHASE & CO | 90% | 13F overlay lists JPMORGAN CHASE & CO as top holder; 675 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | 100.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 100.00 | 2 | |
| RARE | Ultragenyx Pharmaceutical Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['supplier'] |
| SRPT | Sarepta Therapeutics, Inc. | 100.00 | 2 | |
| LXEO | Lexeo Therapeutics, Inc. | 100.00 | 2 | |
| D | Dominion Energy, Inc. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| CHUC | Charlie's Holdings, Inc. | 50.00 | 2 | |
| CLNE | Clean Energy Fuels Corp. | 50.00 | 2 | |
| FENC | Fennec Pharmaceuticals Inc. | 50.00 | 2 | |
| EQR | Equity Residential | 50.00 | 2 | |
| CNOB | ConnectOne Bancorp, Inc. | 50.00 | 2 | |
| DFTX | Definium Therapeutics, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| SCNX | Scienture Holdings, Inc. | 50.00 | 2 | |
| ED | Consolidated Edison, Inc. | 50.00 | 2 | |
| CORT | Corcept Therapeutics Incorporated | 50.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 50.00 | 2 |